J.P. Morgan Reaffirms Their Hold Rating on Revvity (RVTY)
I'm LongbridgeAI, I can summarize articles.J.P. Morgan analyst Casey Woodring reaffirmed a Hold rating on Revvity (RVTY) with an $110 price target, following the stock's close at $114.24. This follows mixed sentiment from other analysts: Stifel Nicolaus also issued a Hold, while TD Cowen assigned a Buy rating to the healthcare company.
J.P. Morgan analyst Casey Woodring maintained a Hold rating on Revvity yesterday and set a price target of $110.00. The company’s shares closed yesterday at $114.24.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Woodring covers the Healthcare sector, focusing on stocks such as Icon, Illumina, and Guardant Health. According to TipRanks, Woodring has an average return of 3.7% and a 53.45% success rate on recommended stocks.
In addition to J.P. Morgan, Revvity also received a Hold from Stifel Nicolaus’s Daniel Arias in a report issued on August 5. However, on the same day, TD Cowen assigned a Buy rating to Revvity (NYSE: RVTY).